GTHP GUIDED THERAPEUTICS INC
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 924515 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY283.1%
TTM net income YoY-15.6%
TTM EPS YoY40.0%
Revenue 3-yr CAGR117.8%
Net income 3-yr CAGR—
Margins
Gross margin80.4%
Operating margin-304.0%
Net margin-446.2%
FCF margin—
EBITDA margin-302.5%
Returns
ROE—
ROA-267.0%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets546.1%
Debt / equity—
Current ratio0.11x
Interest coverage-3.31x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-128.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $92,000 | $0 | $0 | $590,000 | $60,000 | $117,000 | $0 | $1,000 |
| Cost of revenue | $2,000 | $0 | $0 | $132,000 | $25,000 | $38,000 | $0 | $3,000 |
| Gross profit | $90,000 | $0 | $0 | $458,000 | $35,000 | $79,000 | $0 | -$2,000 |
| R&D expense | $204,000 | $34,000 | $45,000 | $127,000 | $136,000 | $133,000 | $74,000 | $140,000 |
| SG&A expense | $384,000 | $423,000 | $451,000 | $1.02M | $362,000 | $658,000 | $267,000 | $323,000 |
| Operating income | -$583,000 | -$478,000 | -$302,000 | -$710,000 | -$485,000 | -$763,000 | -$414,000 | -$534,000 |
| Interest expense | $156,000 | $136,000 | $151,000 | $184,000 | $129,000 | $157,000 | $147,000 | $134,000 |
| Pretax income | -$720,000 | -$605,000 | -$500,000 | -$1.22M | -$742,000 | -$811,000 | -$427,000 | -$652,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$720,000 | -$605,000 | -$500,000 | -$1.22M | -$742,000 | -$811,000 | -$427,000 | -$652,000 |
| EBITDA | -$580,000 | -$476,000 | -$300,000 | -$707,000 | -$483,000 | -$760,000 | -$412,000 | -$532,000 |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.01 | -0.01 | — |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | -0.01 | -0.01 | -0.01 | — |
| Weighted avg. shares (diluted) | 96.54M | 96.54M | 88.84M | — | 81.69M | 78.84M | 68.29M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $111,000 | $12,000 | $369,000 | $63,000 | $87,000 | $185,000 | $115,000 | $388,000 |
| Receivables | $3,000 | $4,000 | $4,000 | $4,000 | $6,000 | $8,000 | $2,000 | $3,000 |
| Inventory | $511,000 | $500,000 | $469,000 | $448,000 | $583,000 | $595,000 | $633,000 | $633,000 |
| Current assets | $734,000 | $527,000 | $911,000 | $605,000 | $799,000 | $811,000 | $811,000 | $1.20M |
| PP&E, net | $9,000 | $11,000 | $13,000 | $16,000 | $18,000 | $18,000 | $21,000 | $23,000 |
| Total assets | $1.38M | $1.20M | $1.60M | $1.32M | $903,000 | $940,000 | $967,000 | $1.38M |
| Current liabilities | $6.93M | $6.17M | $5.96M | $6.64M | $6.47M | $6.38M | $5.90M | $6.16M |
| Long-term debt | $140,000 | $53,000 | $91,000 | — | — | — | — | — |
| Total debt | $140,000 | $53,000 | $91,000 | — | — | — | — | — |
| Total liabilities | $7.51M | $6.96M | $6.78M | $7.33M | $6.55M | $6.41M | $6.00M | $6.27M |
| Shareholders' equity | -$6.14M | -$5.76M | -$5.18M | -$6.01M | -$5.65M | -$5.47M | -$5.03M | -$4.89M |
| Net debt | $29,000 | $41,000 | -$278,000 | — | — | — | — | — |
| Shares outstanding | 98,188 | 96.54M | 96.51M | 86,154 | 83.60M | 78.97M | 77.97M | 65.13M |
| Cash flow statement | ||||||||
| Operating cash flow | -$349,000 | -$319,000 | -$617,000 | -$291,000 | -$277,000 | -$169,000 | -$331,000 | -$332,000 |
| Capital expenditure | — | — | — | $0 | — | — | — | $0 |
| Free cash flow | — | — | — | -$291,000 | — | — | — | -$332,000 |
| Investing cash flow | — | — | — | $0 | — | — | — | $0 |
| Financing cash flow | $448,000 | -$38,000 | $923,000 | $267,000 | $181,000 | $239,000 | $58,000 | $526,000 |
| Depreciation & amortization | $3,000 | $2,000 | $2,000 | $3,000 | $2,000 | $3,000 | $2,000 | $2,000 |
| Stock-based compensation | $22,000 | $11,000 | $68,000 | $25,000 | $22,000 | $329,981 | $19,000 | -$13,000 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.